Clinical Catch-Up: January 18-22 | BioSpace
The Pharma Data
JANUARY 24, 2021
It inked a deal with the National Institute of Allergy and Infectious Diseases (NIAID) to launch a Phase I trial. Brilacidin has shown in vitro to be have antiviral properties against different SARS-CoV-2 strains and other human coronaviruses. Read on to see. COVID-19-Related. It also has robust antimicrobial properties.
52 
Let's personalize your content